Sellas Life Sciences Group Inc
SLS1.630USD
+0.020+1.24%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
163.60MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Sellas Life Sciences Group Inc Unternehmen
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
Unternehmensinformationen
BörsenkürzelSLS
Name des UnternehmensSellas Life Sciences Group Inc
IPO-datumMar 12, 2008
CEODr. Angelos M. Stergiou, M.D.
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeMar 12
Addresse7 Times Square
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10036
Telefon16462005278
Websitehttps://www.sellaslifesciences.com/
BörsenkürzelSLS
IPO-datumMar 12, 2008
CEODr. Angelos M. Stergiou, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Dr. David A. Scheinberg, M.D., Ph.D.
Dr. David A. Scheinberg, M.D., Ph.D.
Independent Director
Independent Director
10.58K
-38.05%
Mr. John W. Varian
Mr. John W. Varian
Independent Chairman of the Board
Independent Chairman of the Board
10.40K
-38.46%
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Aug 17
Aktualisiert: Sun, Aug 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
6.32%
BlackRock Institutional Trust Company, N.A.
3.96%
Marshall Wace LLP
2.58%
Geode Capital Management, L.L.C.
2.09%
Susquehanna International Group, LLP
1.41%
Andere
83.64%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
6.32%
BlackRock Institutional Trust Company, N.A.
3.96%
Marshall Wace LLP
2.58%
Geode Capital Management, L.L.C.
2.09%
Susquehanna International Group, LLP
1.41%
Andere
83.64%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
14.79%
Investment Advisor/Hedge Fund
7.19%
Hedge Fund
2.07%
Research Firm
1.16%
Individual Investor
0.32%
Bank and Trust
0.13%
Pension Fund
0.10%
Venture Capital
0.07%
Insurance Company
0.03%
Andere
74.13%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
100
16.82M
16.86%
+5.40M
2025Q1
95
15.37M
15.79%
+4.85M
2024Q4
82
6.32M
8.71%
-3.29M
2024Q3
79
5.54M
8.62%
-2.91M
2024Q2
81
6.60M
15.25%
-2.78M
2024Q1
80
10.46M
22.59%
+5.00M
2023Q4
78
5.95M
19.06%
+1.91M
2023Q3
79
3.15M
11.52%
-1.61M
2023Q2
83
3.51M
12.82%
-1.46M
2023Q1
86
3.47M
12.66%
-413.28K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
2.84M
2.85%
+546.46K
+23.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
436.33K
0.44%
+3.52K
+0.81%
Mar 31, 2025
Geode Capital Management, L.L.C.
820.44K
0.82%
+86.89K
+11.85%
Mar 31, 2025
Susquehanna International Group, LLP
688.70K
0.69%
+688.70K
--
Mar 31, 2025
State Street Global Advisors (US)
277.03K
0.28%
+49.30K
+21.65%
Mar 31, 2025
Northern Trust Investments, Inc.
164.39K
0.16%
+29.70K
+22.05%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
